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Background: Although the founding members of the INhibitor of Growth (ING) family of histone mark readers, ING1 and ING2,
were defined as tumour suppressors in animal models, the role of other ING proteins in cellular proliferation and cancer
progression is unclear.
Methods: We transduced ex vivo benign prostate hyperplasia tissues with inducible lentiviral particles to express ING proteins.
Proliferation was assessed by H3S10phos immunohistochemistry (IHC). The expression of ING3 was assessed by IHC on a human
prostate cancer tissue microarray (TMA). Gene expression was measured by DNA microarray and validated by real-time qPCR.
Results:We found that ING3 stimulates cellular proliferation in ex vivo tissues, suggesting that ING3 could be oncogenic. Indeed,
ING3 overexpression transformed normal human dermal fibroblasts. We observed elevated levels of ING3 in prostate cancer
samples, which correlated with poorer patient survival. Consistent with an oncogenic role, gene-silencing experiments revealed
that ING3 is required for the proliferation of breast, ovarian, and prostate cancer cells. Finally, ING3 controls the expression of an
intricate network of cell cycle genes by associating with chromatin modifiers and the H3K4me3 mark at transcriptional start sites.
Conclusions: Our investigations create a shift in the prevailing view that ING proteins are tumour suppressors and redefine ING3
as an oncoprotein.
In 2012, it was estimated that 41 million men were diagnosed
with prostate cancer (PC) and 307 000 died from it world-
wide, placing PC as the fifth leading cause of death from
cancer in men (excluding non-melanoma skin cancers) (Ferlay
et al, 2015). PC initiation and progression depend on androgens
and the androgen receptor (AR) (Wong et al, 2014; Ferraldeschi
et al, 2015). Although androgen-deprivation-based therapies
(termed chemical castration) initially benefit most patients, PC
inevitably recurs but in a castrate-resistant and invariably
fatal form. Current PC diagnosis incorporates assessment of
prostate-specific antigen (PSA) levels in patient sera with
trans-rectal ultrasound-guided prostate biopsies. However, PSA
thresholds are unreliable and biopsies are misdiagnosed in
about 30–50% of cases. Although the recently developed urinary
PCA3 (PC gene 3) and PSA-based prostate health index blood
tests offer alternative assessment methods and multiparametric
magnetic resonance imaging improves tumour detection, novel,
more reliable prognostic biomarkers are still required. Thus a
better understanding of the molecular mechanisms driving PC is
vital.
The INhibitor of Growth (ING) family of chromatin readers was
established over 20 years ago with the identification of the tumour-
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suppressor ING1 (Garkavtsev et al, 1996). ING proteins regulate
access to genetic information in part through associating with the
histone H3 trimethylated on lysine 4 (H3K4me3) active gene
expression mark and tethering enzymatic activities to facilitate (e.g.
ING4 via the acetyltransferase HBO1; Hung et al, 2009) or to
restrict (e.g. ING2 via the deacetylase HDAC1; Shi et al, 2006)
access to genetic information. The interaction with H3K4me3 is
mediated via a plant homeodomain (PHD) located at the carboxy
terminus of each ING protein. Although ING1 and ING2 associate
with the mSIN3A/HDAC1 histone deacetylase complex, ING3,
ING4, and ING5 associate with either TIP60, HBO1, or MOZ
histone acetyltransferase complexes (Doyon et al, 2006). Of note,
ING3 is required along with EPC1 for full TIP60 histone
acetyltransferase activity on nucleosomes (Doyon et al, 2004). In
addition, ING3 is part of the ANP32E histone exchange complex
(Obri et al, 2014), which is similar to the core ING3/TIP60
complex (Doyon et al, 2004, 2006). Given that ING1 and ING2
associate with histone deacetylases (HDACs), they are believed to
principally function as transcriptional repressors, while ING3-5
would function as transcriptional activators (Bua and Binda, 2009).
Initially identified as a transcriptional co-activator that
associates with the Tat transactivating factor from human
immunodeficiency virus 1 (HIV-1) (Kamine et al, 1996), TIP60
(Tat interactive protein, 60 kDa) was rapidly found to have histone
acetyltransferase (HAT) activity (Yamamoto and Horikoshi, 1997)
and to potentiate the transcriptional activity of AR (Brady et al,
1999). As an integral part of the TIP60 complex, we hypothesised
that ING proteins could have an unsuspected role in AR signalling,
potentially regulating a transcriptional network and cellular
proliferation. We thus established an inducible expression system
to screen ING proteins for proliferative potential in an ex vivo
human prostate tissue model and identified ING3 as an inducer of
growth. Then, we measured ING3 levels in benign tissues
compared with matched cancer samples and found that elevated
ING3 levels correlate with treatment resistance and poor survival,
corroborating in vitro assays suggesting that ING3 has oncogenic
properties. Indeed, ING3 expression was sufficient to transform
normal human cells as assessed by anchorage-independent growth.
Gene expression profiling identified several cell cycle regulatory
genes as well as AR- and p53-responsive genes, whose expression
was altered in the absence of ING3. The silencing of ING3 in breast
cancer, ovarian cancer, and PC cell line models led to inhibition of
proliferation characterised by a G1/S arrest accompanied by an
induction of apoptosis. Mechanistically, ING3 associates with
chromatin modifiers and H3K4me3 at the transcriptional start site
(TSS) of cell cycle genes to regulate gene expression. Collectively,
we show that ING3 associates with gene promoters to regulate a
transcriptional network that is required for cellular proliferation.
Importantly, ING3 elevated copy number and protein levels in
cancer patients, particularly in treatment-resistant patients,
designate ING3 as a novel marker of poor survival for cancer
patients and an unsuspected oncoprotein. We thus propose to
rename the INhibitor of Growth 3 the INducer of Growth 3 to
retain the gene name while highlighting the potential of ING3 to
promote cellular proliferation.
MATERIALS AND METHODS
Antibodies and plasmids. The cDNA of human ING3 was cloned
by PCR from total RNA extracted from the MCF7 cell line using
forward 50-GGCCAGATCTTTGTACCTAGAAGACTATCTGGA-30
and reverse 50-AGGACTCGAGTTATTTGTGTCTGCTGCCTCT-30
primers, inserted in pCMV-3Tag-1A (Stratagene, Agilent, CA,
USA) in frame with the 3xFLAG tag. The 3xFLAG-tagged ING3
cDNA was also inserted in the pLVX Lenti-X Tet-One inducible
expression system (Clontech, Takara, France) using the In-Fusion
HD enzyme (Clontech). The mouse monoclonal a-ING3 antibody
was previously described and extensively characterised (Nabbi
et al, 2015). The anti-a-tubulin and a-FLAG antibodies, as well as
a-FLAG M2-agarose were purchased from Sigma (Gillingham,
UK). The HRP-conjugated a-GST (ab3416), a-H3 (ab1791), a-
H3K4me3 (ab8580), and a-TIP49A (ab133513) antibodies were
purchased from Abcam (Cambridge, UK).
Cell culture, transfections, and lentiviral transductions. LNCaP,
CWR22Rv1, MCF7, and PC3 cells were obtained from American
Type Culture Collection (Manassas, VA, USA), while MX-1, PEO1,
and PEO4 cells were obtained from the Northern Institute for
Cancer Research authenticated cell bank. Cells were maintained in
RPMI 1640 media supplemented with 2mM L-glutamine (Invitro-
gen, Paisley, UK) and 10% (v/v) foetal calf serum (FCS) at 37 1C in
5% CO2. LNCaP-AI variant cell line was derived in-house by
culturing LNCaP cells in steroid-depleted media to allow for the
development of androgen independence (Lu et al, 1999). Cell lines
were maintained for up to 30 passages or a maximum of 2 months
of continuous culturing. As per institutional policy, cell lines were
tested for mycoplasma on a tri-monthly basis. For p53 ChIP
experiments, U2OS were maintained in modified McCoy’s 5A
medium supplemented with GlutaMAX and 10% FCS. Prolifera-
tion was measured by live cell imaging four times a day with the
Incucyte system for 114 h postsilencing. Lentiviral particles were
generated by co-transfecting HEK293T with pLVX-3xFLAG-ING3
(ING3WT, ING3Y362A, or ING3W385A), pMD2.G, and psPAX2
(latter two were gifts from Didier Trono; Addgene (Cambridge,
UK) 12260 and 12259, respectively) and used as described
previously (O’Neill et al, 2014). The expression of FLAG-ING3
was induced using doxycycline at 10 ngml 1.
Ex vivo culture. Benign prostatic hyperplasia (BPH) samples were
obtained from cancer-free patients as established by the Pathology
Department at the Freeman Hospital (Newcastle upon Tyne, UK).
The tissue samples were obtained with full ethical approval from
Newcastle & North Tyneside 1 NHS Strategic Health Authority
Local Research Ethics Committee (reference 15/NE/0400). All
methods were performed in accordance with the relevant guide-
lines and regulations. BPH samples were removed surgically
following patient’s written informed consent and placed in ice-cold
culture media. Within 48 h from the surgery, tissues were dissected
to 1mm3 pieces and cultured in duplicates on gelatin sponges
(Spongostan, Johnson & Johnson, New Brunswick, NJ, USA)
presoaked in culture media supplemented with 1 antimycotic
solution (Sigma), 10mgml 1 hydrocortisone, and 10 mgml 1
insulin solution from bovine pancreas (Sigma) as previously
described (Centenera et al, 2012). Ex vivo explants were transduced
with empty vector (pLVX) or FLAG-ING3 lentiviral particles in
media supplemented with 10 ngml 1 of doxycycline and tissues
were cultured for 72 h. At the termination of the experiments,
samples were immediately placed in 4% formalin for 1 h followed
by processing in ethanol then xylene and finally paraffin
embedding. Formalin-fixed paraffin-embedded tissues were
stained as indicated and scored automatically using the Aperio
imaging system (Milton Keynes, UK). Error bars represent s.e.m. of
three independent patient samples.
Anchorage-independent growth. Normal human dermal fibro-
blasts (NHDF) were isolated from juvenile foreskin (PromoCell
C-12300, Heidelberg, Germany) and maintained in fibroblast
growth medium (PromoCell C-23010). NHDF were transduced
with lentiviral particles, ING3 expression was induced with
doxycycline (10 ngml 1), and 48 h later cultured in fibroblast
media containing 0.56% methylcellulose. Fibroblasts were seeded at
a density of 2500 cells per well in a 24-well plate and incubated at
37 1C in 5% CO2 for 14 days followed by imaging with IncuCyte
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and automated colony counting. Transformation assays with 3T3-
L1 murine fibroblasts were performed essentially as with NHDF
but were seeded at 250 cells per well in a 24-well plate.
siRNA gene silencing and gene expression analysis. The ING3
targeting siRNA sequences were (no.1) CAAUCACCAUGCU-
CAUUCA[dTdT] and (no.2) CUAUAGAAUGGUUCCAUUA
[dTdT]. Cells were transfected with siRNA using RNAiMax
(Invitrogen) according to the manufacturer’s instructions and
incubated in culture media for 96 h prior to cell lysis and analysis
by immunoblotting or real-time qPCR using specific primers
(sequences available in Supplementary Table S1). For real-time
qPCR, total RNA was extracted using TRIzol (Invitrogen, 15596-
026), RNA quality and yields were assessed using a NanoDrop
2000 (NanoDrop, UK), 1 mg of total RNA was reverse transcribed
using SuperScript VILO (Invitrogen, 11755-050), and qPCR was
performed using QuantiTect SYBR Green (QIAGEN, 204143,
Manchester, UK) on an ABI PRISM 7900HT Sequence Detection
System (Applied Biosystems, Foster City, CA, USA). Data were
tested for parametric distribution. Parametric data were analysed
using appropriate t-tests or ANOVA with Bonferroni’s comparison
test for multiple group comparisons. Non-parametric data were
analysed using Wilcoxon signed-rank test. By convention, P-values
are marked as follows; ***Po0.001, **Po0.01, and *Po0.05.
Microarray. LNCaP cells were transfected with siRNA and
cultured in steroid-depleted media for 72 h followed by 24 h
stimulation with 10 nM dihydrotestosterone (DHT). Total RNA
was extracted (RNeasy Plus, QIAGEN) and its purity confirmed
both using the NanoDrop and Bioanalyser. Samples were
processed on the Illumina Human HT-12 platform by High
Throughput Genomics (The Wellcome Trust Centre for Human
Genetics, University of Oxford, Oxford, UK) and analysed using
the GenomeStudio software (Illumina, Cambridge, UK). Experi-
ments consisted of four independent biological repeats of
scrambled control-, siRNA no.1-, or siRNA no.2-treated samples.
Analysis was performed by comparing ING3 siRNA to scrambled
siRNA and results compiled.
Immunohistochemistry. Tissue microarrays (TMA) containing
0.6mm cores of benign prostatic hyperplasia (BPH) (n¼ 41), PC
(n¼ 81), and control tissues, including breast, kidney, placenta,
ovary, and liver, were used (Coffey et al, 2013). These samples were
obtained with full ethical approval from the Northumberland,
Tyne, and Wear NHS Strategic Health Authority Local Research
Ethics Committee (reference 2003/11). Antigens were retrieved by
pressure cooking the TMA in 10mM citrate pH 6.0 followed by
staining the tissues with an extensively validated (Nabbi et al, 2015)
mouse monoclonal a-ING3 antibody. The TMA were indepen-
dently scored by 2 individuals using the 0–300 H-score method
(Kirkegaard et al, 2006). Briefly, percentage and intensity of
staining for positive cells was estimated (0, 1, 2, 3) using the
following equation H-score¼ (% of cells with low-level
positivity)þ 2 (% of cells with medium-level positivity)þ 3 (%
of cells with high-level positivity).
Flow cytometry. Cell cycle profiles were generated by propidium
iodide (PI) staining; cells were permeabilised with 1% Triton X-100
and incubated with 1 mgml 1 RNaseA and PI followed by analysis
using a BD FACScan, as described previously (Burska et al, 2013).
Levels of apoptosis were analysed after 96 h of gene silencing by
Annexin V assay (BD, Oxford, UK) according to the manufac-
turer’s instructions and analysed using a BD FACScan. Cells were
stained for both Annexin V and PI positivity and, during analysis,
divided into quarters representing normal cells, necrotic cells, and
apoptotic cells.
Chromatin immunoprecipitation. LNCaP cells were maintained
in steroid-depleted media for 72 h followed by stimulation with
10 nM DHT for 120min. Then ChIP were performed as described
previously (Gaughan et al, 2002). To quantify the binding of AR or
ING3 at ARE or TSS, we performed real-time qPCR on ChIPed
DNA using specific primers (sequences available in Supplementary
Table S2). Data are represented as percentage of input fold change
(% input¼ 100 2(CTinputCTChIP)); CT refers to cycle threshold.
RESULTS
ING3 functions as an oncoprotein. By maintaining native tissue
architecture, including epithelia and stroma, ex vivo 3D culture of
intact tissues is a more representative and robust disease model of
cancer than cell line or animal xenograft models (Centenera et al,
2012; Centenera et al, 2013). To evaluate the proliferative role of
ING proteins, we used a doxycycline-inducible lentiviral system
composed of a minimal CMV promoter regulated by tetracycline-
response elements (TRE). Ex vivo tissue cultures of benign prostate
hyperplasia (BPH) tissues isolated from three different cancer-free
patients were transduced with lentiviral particles and exposed to
doxycycline to induce the expression of full-length wild-type
FLAG-tagged ING proteins or FLAG-p53, as a known tumour-
suppressor control. The expression of INGs and proliferation
(mitosis) marker H3S10phos were assessed by IHC. In agreement
with ING1b being a tumour suppressor, H3S10phos levels were
decreased similarly to p53 compared with the empty vector control
(Figure 1A). Interestingly, samples expressing ING4 had increased
levels of H3S10phos, while H3S10phos was lower in ING5 samples
(Figure 1A). These results confirm the tumour-suppressive
functions of ING1b and suggest that ING4 may have pleiotropic
roles (i.e., reported to be a tumour suppressor but appears to
stimulate proliferation in prostate tissues).
Strikingly, ING3-transduced tissues had high levels of
H3S10phos (not shown) thus, as ING3 associates with the AR co-
activator TIP60, we extended our investigations and transduced
ING3 in ex vivo tissues from three additional patients and
confirmed that ING3 expression enhances H3S10phos levels
(Figure 1B), suggesting that ING3 has oncogenic properties. To
test the hypothesis that ING3 may be an oncoprotein, we expressed
ING3 in NHDF in a classical anchorage-independent growth assay.
In agreement with these observations, ING3 expression in NHDF
was sufficient to stimulate anchorage-independent growth
(Figure 1C), suggesting cellular transformation and further
supporting the notion that ING3 is an oncoprotein. To further
validate ING3 oncogenic properties, transformation assays were
also performed in 3T3-L1 murine fibroblasts using p53 as an
established tumour-suppressor control and RASV12 as an
established oncoprotein control. As expected, p53-expressing cells
did not form colonies, while RASV12-expressing cells formed
colonies (Figure 1D). Importantly, ING3 expression also led to
colony formation (Figure 1D), confirming that ING3 expression
does transform cells.
Elevated ING3 expression is a marker of poor prognosis in
cancer patients. Analysis of various cancer databases (Cerami
et al, 2012; Gao et al, 2013) showed a significant increase in the
copy number of ING3 in breast cancer, melanoma cancer, ovarian
cancer, and PC patients. A more thorough analysis of The Cancer
Genome Atlas (TCGA) database showed that an increased copy
number of ING3 correlates with development of prostate
adenocarcinoma (Supplementary Figure S1A). These results
suggest that ING3 may have a role in PC initiation or progression.
We thus compared ING3 copy number with the disease outcome
and observed that patients with increased ING3 copy number were
less likely to undergo remission (Supplementary Figure S1B) and
relapsed earlier (Supplementary Figure S1C). These results imply a
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correlation between the amplification of ING3 and poor outcome
for PC patients and a potential application of ING3 as a biomarker.
To further investigate the expression of ING3 in PC tissues, we
used an extensively characterised and validated ING3 antibody,
which was also optimised for IHC (Nabbi et al, 2015). Specifically,
we examined ING3 protein levels by IHC analysis of a TMA
(described previously; Coffey et al, 2013) from BPH and PC
specimens (Figure 2A) and observed elevated protein levels of
ING3 in PC when compared with BPH samples (Figure 2B). In
addition, ING3 levels were found to be elevated in treatment-
resistant compared with castration-sensitive PC patients
(Figure 2C). Elevated ING3 protein levels also correlated with
decreased overall survival (Figure 2D). Finally, we observed that
ING3 levels in the TMA samples correlate with an increase in
proliferation markers MCM2, Ki-67, and Geminin (Supplementary
Figures S1D–F). Together, our data indicate that ING3 copy
number and ING3 protein levels correlate with cellular prolifera-
tion and that ING3 could be used as a biomarker of poor prognosis
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Figure 1. Ex vivo screen and transformation assays. (A) Ex vivo patient BPH tissues were transduced with negative control vector pLVX, positive
control FLAG-p53, or FLAG-INGs. The expression of these genes was induced with doxycycline. Tissues were fixed and processed for staining by
IHC for H3S10phos or FLAG. (B) Ex vivo patient benign tissues were transduced with control (pLVX) or FLAG-tagged ING3-expressing lentiviral
particles. The expression of proliferation marker H3S10phos and ING3 was assessed by IHC. (C) Normal human fibroblast were transduced with
pLVX or FLAG-ING3 and anchorage-independent growth assessed by colony-formation assays in methylcellulose. The transformation assays were
performed in three independent experiments and combined in one graphic with representative pictures. (D) As in panel (C) but performed in 3T3-
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significant. ING=INhibitor of Growth.
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in PC. Our data strikingly indicate that ING3 does not behave as a
tumour suppressor but rather as an oncoprotein.
Identification of an ING3 transcriptional network. As ING3
associates with methylated histones and chromatin-modifying
enzymatic complexes and to understand how ING3 may function
as an oncoprotein, we performed a microarray gene expression
analysis. Given that ING3 is a potential AR co-regulator, we
addressed the question whether ING3 was required for AR-
dependent transcription upon androgen stimulation. Following the
rationale that DHT would have a minimal impact on AR-
independent transcription, the microarray survey was performed
on androgen-stimulated LNCaP cells. To validate the specificity of
the siRNAs used, the microarray data for each gene was plotted
and the overlay of both siING3 no.1 and siING3 no.2 showed
nearly identical gene expression profiles (Supplementary Figure
S2). Upon silencing the expression of ING3 in the LNCaP PC cell
line, we identified a number of genes that were either upregulated
or downregulated (see Supplementary Table S3 for complete list).
Among the top 25 downregulated genes, cell cycle regulators
CCNA2, CCNB2, CDC2, CDC20, and AURKA were identified
(Figure 3A). The silencing of ING3 was confirmed by immuno-
blotting using an extensively validated antibody (Nabbi et al, 2015)
(Figure 3B) and real-time qPCR (Figure 3C). Importantly, only a
single band appeared on immunoblots and decreased upon ING3
silencing (Figure 3B). Interestingly, the expression of MELK highly
correlates with cell cycle genes AURKB, CCNB2, TOP2A, and
UBE2C, which are upregulated in high-grade PC (Kuner et al,
2013) and appear to form a transcriptional network whose
expression requires ING3 (Figure 3A), suggesting that ING3
regulates this pathway. Similarly, the expression of several genes
from the EGFR inside-out pathway (CCNB2-HMMR-KIF11-
NUSAP1-PRC1-SLC2A1-UBE2C) (Zhou et al, 2015) require the
expression of ING3 (Figure 3A). The requirement of ING3 for the
expression of these genes was validated by real-time qPCR (Figures
3D–J). Although ING3 associates with histone acetyltransferase
activity and thus should mainly function as a transcriptional
activator, we observed that a number of genes were upregulated in
the absence of ING3, including CAMK2N1 (Figure 3A and D), a
gene that inhibits proliferation of PC cells (Wang et al, 2014a, b),
the cyclin-dependent kinase inhibitor CDKN1A (p21CIP1/WAF1),
and the antiproliferative gene BTG1 (Figure 3A). Together, these
results demonstrate that ING3 directly or indirectly regulates genes
involved in cell cycle progression and cell survival.
Silencing of ING3 expression regulates genes associated with cell
cycle progression and slows cellular proliferation. In agreement
with ING3-stimulating cellular proliferation (Figure 2E), close to
half of the genes found to be affected by the depletion of ING3 are
involved in cell cycle progression, including cyclin A (CCNA2)
(Figure 3A and 4A). Also, about a quarter are DNA-binding
factors, and a small, but significant, portion of genes regulate cell
death. We validated by real-time qPCR the increased expression of
CDKN1A (Figure 4B) and CDKN1B (Figure 4C) in PC and breast
cancer cells.
Although the exogenous expression of ING3 in various cell lines
presumably induces proliferation defects (Nagashima et al, 2003;
Chen et al, 2010), little is known about the roles of ING3 in the
control of cellular proliferation and the molecular mechanisms
underlying its functions. To determine the potential role of ING3
in regulating cellular proliferation, we silenced the expression of
ING3. Consistent with ex vivo experiments (Figure 1B), silencing
the expression of ING3 reproducibly led to severe proliferation
defects in PC cells. Specifically, LNCaP (DHT sensitive (DHTs))
cells treated with either siING3 no.1 or no.2 barely proliferated
over a 5-day period (Figure 4D). Interestingly, silencing of ING3
expression had comparable consequences on the proliferation of
the androgen-independent LNCaP-AI (DHTi) isogenic cell line
(Supplementary Figure S3). Similarly, the proliferation of PC
(CWR22Rv1 and PC3), breast cancer (MCF7 and MX-1), and
ovarian cancer (PEO1 and PEO4) cell lines (see Supplementary
Table S4 for characteristics) were also affected by silencing of ING3
(Supplementary Figure S3). To further investigate the potential
causes of cellular proliferation defects induced by the silencing of
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ING3, we performed cell cycle analysis of the LNCaP cell line. In
agreement with slower proliferation rates (Figure 4D), ING3-
silenced cells had a marked increase in the G0/G1 phase population
accompanied by lower S and G2/M populations (Figure 4E). The
increased G0/G1 population translates into an increase in G1/S ratio
(Figure 4F), a hallmark of cell cycle arrest. Furthermore, we
observed a small but consistent increase in the subG1 population
(Figure 4E), suggesting that the silencing of ING3 may induce
apoptosis. Indeed, Annexin V staining of ING3-silenced cells
showed a threefold increase in apoptotic cells (Figure 4G),
consistent with severely reduced proliferation as well as accumula-
tion of G1/S and subG1 populations (Figures 4D–F). These results
demonstrate that ING3 is essential for the proliferation of a broad
range of cancer cell types, further demonstrating the oncogenic
properties of ING3.
ING3 regulates the expression of androgen-responsive genes.
Hypothetically, ING3 could regulate AR-dependent transcription
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via the acetyltransferase TIP60 (Brady et al, 1999; Doyon et al,
2004, 2006), which regulates cellular proliferation and the
expression of cell cycle genes. We thus performed an extensive
survey of known AR-regulated genes from the ING3 transcrip-
tional network. We identified three genes requiring the expre-
ssion of ING3 for normal expression and a dozen that were
stimulated in the absence of ING3 (Figure 5A). To assess
whether androgens affect ING3-regulated genes, all validation
experiments were performed with and without DHT. Interestingly,
through validation of the microarray analysis, we identified
a novel androgen-responsive gene, KIF20A, which is stimulated
by DHT, but requires ING3 for expression (Figure 5B). Reduced
levels of ING3 (Figure 5C) did not affect the expression of the AR
itself (Figure 5C) but nonetheless appeared to further stimulate the
DHT-induced expression of androgen-responsive genes such as
PSA (KLK3), TMPRSS2, and KLK2 (only with siING3 no.1)
(Figure 5C), while having inconclusive effects on the expression of
other androgen-responsive genes, such as NKX3.1 (Figure 5C).
ING3 regulates the expression of a subset of p53-responsive
genes. Given the potential role of ING3 in the regulation of p53-
dependent transcription (Nagashima et al, 2003), which also
regulates the expression of cell cycle genes, proliferation, and
apoptosis, we compared known p53-responsive genes (Riley et al,
2008) to the list of genes identified in the ING3 transcriptional
network (highlighted in Supplementary Figure S4). Out of the 129
known p53-responsive genes (Riley et al, 2008), 7 were down-
regulated (5%) and 13 upregulated (10%) following the silencing of
ING3 expression (Figure 5D). The increased expression of BAX
(Figure 5D) was validated by real-time qPCR in both LNCaP and
breast cancer MCF7 cell lines (Figure 5E). Notably, the induced
expression of CDKN1A (Figure 5D) had already been validated in
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LNCaP and MCF7 (Figure 4B). The expression of other p53-
regulated genes not identified in the microarray analysis was also
investigated. In particular, we found that the transcription of
FOXO3, PML, and NOXA was activated by the silencing of ING3
in LNCaP (Figure 5F), whereas only PML was induced in MCF7
(Figure 5F). These results, alongside published work (Nagashima
et al, 2003), suggest that ING3 functions as a p53 co-factor for a
subset of genes.
Characterisation of ING3 interaction with H3K4me3. As the
PHD of ING proteins has a central role in controlling proliferation,
survival, and other cellular functions, we investigated this key
region within ING3. The PHD of ING3 (ING3PHD) shares
extensive primary amino-acid sequence similarity with other
family members (Figure 6A). Specifically, tyrosine 362 (Y362),
serine 369 (S369), and tryptophan 385 (W385) (Figure 6A, red
boxes) are perfectly conserved with amino acids that form an
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H3K4me3-binding aromatic cage in other ING proteins (Shi et al,
2006; Hung et al, 2009). Thus we predicted the structure of
ING3PHD using Phyre
2 (Kelley and Sternberg, 2009) and super-
imposed it with the structure of ING4PHD-bound to H3K4
me3
using CCP4mg (McNicholas et al, 2011) (Figure 6B). The overlay
of ING3PHD and ING4PHD suggests that Y362, S369, and W385 of
ING3 would indeed form an aromatic cage similar to ING4 and
thus mediate interactions with H3K4me3. To confirm their role in
H3 binding, the Y362 and W385 sites were converted to alanine
(A) and used to investigate the interaction between ING3PHD and
histones purified from calf thymus. This experiment confirmed
that the PHD of ING3 does bind to histone H3 (Figure 6C).
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In addition, the failure of ING3PHD[W385A] to bind to H3
(Figure 6C) suggests that the aromatic amino-acid residue is
responsible for interactions with H3K4me3, as predicted (Figures
6A and B). However, ING3PHD[Y362A] retained wild-type H3-
binding capacity (Figure 6C). The interaction between ING3PHD
and H3 was further investigated using synthetic H3 peptides
harboring mono-, di-, or tri-methyl groups at K4 or K9, as well as
unmodified or tri-methylated H3K36. As expected, ING3PHD
specifically bound the methylated H3K4 forms, with an affinity
increasing (H3unmodooH3K4me1oH3K4me2oH3K4me3) conco-
mitantly with the methylation state of K4 (Figure 6D). Interest-
ingly, both ING3PHD and ING3PHD[Y362A] associated more stably
with H3K4me2/3, while the ING3PHD[W385A] mutant completely
failed to interact with any histone modifications assessed
(Figure 6E). Similar interaction results were obtained between
ING3 and nucleosomes, where ING3Y362A retained wild-type
binding to H3, whereas ING3W385A failed to associate with H3
(Figure 6F). For subsequent gene expression and chromatin
immunoprecipitation (ChIP) experiments, it is worth mentioning
that both ING3Y362A and ING3W385A forms retain wild-type
capacity to associate with subunits of the TIP60 complex, such as
TIP49A (Figure 6G). Together, these results establish that the
PHD of ING3 associates with methylated H3K4 and requires
conserved amino-acid residues that, based on sequence similarities
to other ING protein and structure prediction, form an aromatic
cage.
ING3 associates with the TSS of cell cycle genes. We have so far
demonstrated that ING3 is required for the expression of an
intricate transcriptional network involved in regulating the
proliferation of cancer cells. However, ING3 may directly or
indirectly regulate the expression of these genes. We thus
performed ChIP experiments to investigate the association of
ING3 with genes that were identified in our gene expression survey
(Figure 3). Also, as the PHD of ING3 binds H3K4me3 (Figure 6), a
modification marking the TSS of most genes (Barski et al, 2007),
and a similar molecular mechanism for the regulation of gene
expression was described for ING2 (Shi et al, 2006) and ING4
(Hung et al, 2009), we investigated that region in particular. Upon
induction of ING3 expression (Figures 7A and B), the expression
of BAX, KLK2, TMPRSS2, and CDKN1A (genes induced in ING3-
silenced cells) was repressed (Figures 7C–F). Interestingly, ING3WT
and ING3Y362A were found at the TSS of CDKN1A, while the
H3K4me3-defective mutant ING3W385A was absent from this region
(Figure 7G). Importantly, all ING3 forms were absent from a
control region situated approximately 500 base pairs upstream
( 500 bp) of the TSS (Figure 7H). In agreement with ING3
repressing the expression of CDKN1A, inhibition of HDAC activity
with trichostatin A (TSA) completely relieved ING3-mediated
transcriptional repression of CDKN1A (Figure 7I). An HDAC-
dependent and TSA-sensitive transcriptional repression mechan-
ism was further explored, and we found that ING3 associates with
HDAC1 (Figure 7J). Given that ING proteins often cooperate with
p53, we investigated whether p53 and ING3 could occupy the same
sites on the CDKN1A promoter in U2OS human osteosarcoma
cells (wild-type p53). Interestingly, ChIP experiments revealed that
both p53 and ING3 occupied the TSS of CDKN1A (Figure 7K).
Moreover, in response to DNA damage induced by doxorubicin,
p53 vacated the TSS while ING3 bound more avidly (Figure 7K).
Despite this dynamic occupancy at the TSS, ING3 did not occupy
the p53-binding site upstream of CDKN1A (Figure 7K).
In addition, further supporting the role of ING3 in regulating
the expression of cell cycle genes, ING3 was also found at the TSS
of CCND1 and PCNA but remained undetectable at both the
androgen response element (ARE) AREIII of PSA and the ARE of
KLK2 (Supplementary Figure S5). Interestingly, the presence of AR
at the ARE of KLK2 was reduced when ING3 was expressed
(Supplementary Figure S5), potentially explaining the increased
KLK2 expression observed in ING3-silenced cells (Figure 5C).
These results suggest that ING3 indirectly regulates the expression
of AR-regulated genes (e.g., KLK2 and PSA). However, ING3 also
appears to use a direct mechanism to regulate gene expression
involving the binding to H3K4me3 at the TSS of cell cycle genes
(e.g. CDKN1A) to regulate their expression. Taken together with
the histone interaction studies (Figure 6), these results demonstrate
that ING3 associates with H3K4me3 at the TSS of cell cycle genes
via its PHD to regulate gene expression.
In conclusion, ING3 associates with TSSs to regulate the
expression of an intricate transcriptional network involving cell
cycle genes as well as AR- and p53-dependent genes to control the
proliferation of cancer cells. Elevated levels of ING3 correlate with
increased cellular proliferation and lower survival of PC patients
and, as such, represents a novel marker of poor prognosis for PC
patients and herein redefined as an oncoprotein.
DISCUSSION
Genetic deletion of the Ing1 locus in a mouse model leads to early
onset and increased incidence of lymphomas (Kichina et al, 2006).
The Ing1 / animals also harbour increased sensitivity to
g-radiation (Kichina et al, 2006). Deletion of the p37Ing1 isoform
in a mouse model causes spontaneous development of follicular
B-cell lymphomas (Coles et al, 2007). Similarly, the Ing2 /
animals have a threefold higher incidence of soft-tissue sarcomas
(Saito et al, 2010), providing concrete evidence that at least Ing1
and Ing2 are bona fide tumour suppressors. However, the evidence
that ING3-5 are tumour suppressors is minimal and largely based
on adenovirus delivery and supraphysiological overexpression or
correlative expression studies. Indeed, silencing of ING4 prevents
the transition from the G2/M phase to G1 phase of the cell cycle,
while silencing of ING5 results in S-phase blockade (Doyon et al,
2006). Moreover, the Ing4 / mouse model does not develop
cancer under reported experimental conditions (Coles et al, 2010),
suggesting that these proteins are not tumour suppressors, or have
complex yet unidentified cellular functions. Indeed, as recently
reported by one of our groups, ING3 is expressed preferentially in
proliferating cells (Nabbi et al, 2015), suggesting that ING3 may
not inhibit growth but rather drive cellular proliferation. In
agreement, we have found elevated levels of ING3 in various
cancers and using an ex vivo human tissue explant model
demonstrated that ING3 does have oncogenic properties by
stimulating cellular proliferation. Precisely, our data demonstrate
that (i) ING3 levels are elevated in PC patients and correlate with
poor outcome; (ii) ING3 is required for the proliferation of breast
cancer, ovarian cancer, and PC cell lines; and (iii) ING3 expression
is sufficient to elicit anchorage-independent growth. Together,
these results strongly suggest that ING3 functions as an
oncoprotein.
Herein we have identified ING3 as a cellular proliferation-
regulating factor. Interestingly, loss of ING3 expression led to
decreased expression of MELK, UBE2C, TOP2A, CCNB2, and
AURKB. These genes have been reported to be highly expressed in
high-grade PC patients (Kuner et al, 2013), while CAMK2N1 forms
a transcriptional network with NUSAP, UBE2C, and HMMR whose
expression regulates proliferation of treatment-resistant cancer
cells (Wang et al, 2014a). In addition, the silencing of ING3
expression led to proliferation defects in a wide array of cancer cell
models, including treatment-sensitive and -resistant PC cell lines,
suggesting that inactivation of ING3 functions could be a viable
therapeutic avenue to eliminate cancer cells in early as well as in
advanced cases.
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Notably, silencing of ING3 resulted in decreased AURKA and
AURKB expression (Supplementary Table S3), two H3S10 kinases,
in agreement with increased H3S10phos in cells expressing ING3
(Figure 1B).
Consistent with previous studies (Kim et al, 2016) showing that
the ING3PHD[Y362A]-H3K4
me3 interaction has a Kd of 46 mM,
compared with 0.9 mM for ING3PHD-H3K4
me3, 3.0mM for
ING3PHD-H3K4
me2, and 23 mM for ING3PHD-H3K4
me1, we found
A
C
F
I J K
G H
D E
B
pL
VX
pLV
X
ING
3 WT
ING
3 Y3
62
A
ING
3 W3
85
A
pLV
X
ING
3 WT
ING
3 Y3
62
A
ING
3 W3
85
A
pLV
X
ING
3 WT
ING
3 Y3
62
A
ING
3 W3
85
A
pLV
XIgG
ING
3 WT
ING
3 Y3
62
A
ING
3 W3
85
A
pLV
XIgG
ING
3 WT
ING
3 Y3
62
A
ING
3 W3
85
A
pLV
X
ING
3 WT
ING
3 Y3
62
A
ING
3 W3
85
A
pLV
X
ING
3 WT
ING
3 Y3
62
A
ING
3 W3
85
A
pL
VX
-IN
G
3
pL
VX
-IN
G
3 Y
36
2A
pL
VX
-IN
G
3 W
38
5A
α-FLAG
52 kDa
40
50
1.5
1.0
0.5
0.0
1.5
1.0
0.5
0.0
1.5
FLAG-ING3
YFP
– + – +
HDAC1 TSS
p53-binding site
95 kDa
52 kDa
42 kDa
34 kDa
26 kDa
95 kDa
52 kDa
42 kDa
34 kDa
26 kDa
α-YFP (I.P.)
α-YFP (I.P.)
1.0
0.5
0.0
25
20
15
10
5
0
pLVX ING3
TSA– TSA+
1.5 3
2
1
0
12
8
8
6
4
2
0
DOX– DOX+
IgG p5
3
ING
3
4
0
1.0
0.5
0.0
1.5
NS
NS
NS
1.0
0.5
0.0
1.5
1.0
0.5
0.0
** *** ***
***
***
*** **
***
*
*
*
NS
*
***
*** ***
** *** ****
ING3
BAX
CDKN1A
CDKN1A
ING3
CDKN1A TSS CDKN1A -500 bp
KLK2 TMPRSS2
30
20
10
0
17 kDaα-H3
Ex
pr
es
sio
n
(H
PR
T1
)
Ex
pr
es
sio
n
(H
PR
T1
)
Ex
pr
es
sio
n
(H
PR
T1
)
Ex
pr
es
sio
n
(H
PR
T1
)
Ex
pr
es
sio
n
(H
PR
T1
)
En
ric
hm
en
t
En
ric
hm
en
t
En
ric
hm
en
t
En
ric
hm
en
t
Ex
pr
es
sio
n
(H
PR
T1
)
Ex
pr
es
sio
n
(H
PR
T1
)
Figure 7. ING3 associates with H3K4me3 at TSSs. (A) A tetracycline-inducible system was used to express FLAG-tagged ING3 (predicted molecular
weight of B50 kDa) forms in LNCaP cells. (B) The expression of ING3, (C) BAX, (D) KLK2, (E) TMPRSS2, and (F) CDKN1A was assessed by real-
time qPCR from total RNA isolated from ING3-expressing LNCaP cells. (G) ChIP experiments of FLAG-ING3 at the TSS of CDKN1A using a
FLAG antibody. (H) As in (G), but real-time qPCR assay was performed at a control region about 500 base pairs ( 500bp) from the TSS of
CDKN1A (**Po0.01, ***Po0.001, and NS indicates not significant, as calculated by t-test). (I) FLAG-ING3 was expressed as in (B–F), but in the
absence (TSA ) or presence (TSAþ ) of the histone deacetylase Trichostatin A (TSA), then the expression of CDKN1A was assessed by real-time
qPCR. (J) FLAG-ING3 and YFP-HDAC1 were co-expressed in HEK293T cells, immunoprecipitated with a-FLAG M2 agarose, and analysed by
immunoblotting using a-GFP antibody (recognises all GFP variants). (K) ChIP experiments were conducted in U2OS cells in the absence (DOX ) or
presence (DOXþ ) of doxorubicin. By convention, *Po0.05, **Po0.01, ***Po0.001, and NS indicates not significant, as calculated by t-test. When
not indicated, P-values are not significant. ING¼ INhibitor of Growth; TSS¼ transcriptional start site.
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that ING3PHD[Y362A] retains H3K4
me3-binding capacity (Figures
6C, E, and F). Interestingly, the ING3PHD[S369A]–H3K4
me3
interaction, with a Kd of 1.5 mM, also retains binding capacity
(Kim et al, 2016). Although highly conserved, Y362 is dispensable
for the ING3PHD–H3K4
me3 interaction, unlike the corresponding
Y198 in ING4PHD (Hung et al, 2009) or Y214 in ING2PHD (Shi
et al, 2006). The Phyre2-predicted structures of ING3PHD suggest
that Y362 may be positioned away from the aromatic cage
(Figure 6B and Supplementary Figure S6), leaving the binding
burden on W385 and a different mode of interaction to methyl-
lysine. Interestingly, the structure predictions including or
excluding PNEPR peptide preceding Y362 suggest that the
sequence located on the amino side of the PHD may be flexible
and thus may fold upon binding to H3K4me3. Further structural
biology investigations will be required to elucidate the precise
mode of interaction between ING3PHD and H3K4
me3 and how it
differs from other INGs.
The importance of the role played by ING3 in tightly controlling
cellular proliferation of cancer cells is also highlighted by the loss of
expression of several cyclin genes (CCNA2, CCNB1, CCNB2, and
CCND1) and gain of cell cycle inhibitors (CDKN1A and CDKN1B)
as well as apoptotic genes (BAX) concomitant with the silencing of
ING3. Importantly, ChIP analysis located ING3 at the TSS of genes
upregulated (i.e., CDKN1A) and downregulated (e.g., CCND1) in
the absence of ING3, demonstrating that ING3 has a direct role in
controlling the expression of genes associated with cellular
proliferation. However, as ING3-regulated genes can be either
negatively or positively regulated in the absence of ING3, there
would be more than one transcriptional mechanism involved.
Potentially, ING3 may positively regulate gene expression via
TIP60 histone acetyltransferase activity (Doyon et al, 2004) and
negatively regulate transcription via an ANP32E histone exchange
mechanism (Obri et al, 2014) or via HDAC1, which we found in
association with ING3 (Figure 7J). Indeed, the ING3-mediated
transcriptional repression of CDKN1A was completely relieved by
the deacetylase inhibitor Trichostatin A (Figures 7I), demonstrat-
ing that ING3 can silence gene expression via histone deacetyla-
tion. Future investigations should address the acetylation state of
histones at ING3-bound chromatin sites as well as the presence of
histone variants deposited by ANP32E. Interestingly, according to
the TCGA database and in agreement with our microarray
analysis, the expression of several cell cycle genes correlated in a
similar way with the expression of ING3 in human PC
(Supplementary Figure S7). Although ING3 was previously
reported to activate the p53-responsive gene CDKN1A using a
transient luciferase reporter assays in colon carcinoma cells
(Nagashima et al, 2003; Doyon et al, 2006), we observed that
silencing of ING3 induced the expression of CDKN1A in breast
cancer and PC cells (Figure 4B), whereas exogenous expression of
ING3 driven by a doxycycline-inducible system repressed the
expression of CDKN1A (Figures 7F and I). We can only speculate
on the causes of these discrepancies, but they are most likely due to
the different cell lines or systems used. Although several ING
proteins have been reported to associate with p53, we failed to
observe any interactions between p53 and ING3 in LNCaP cells
under mild immunoprecipitation conditions. In ChIP experiments
at CDKN1A, we found p53 at the p53-binding site, but ING3 was
not detected. In addition, p53 could be detected at the TSS, while
ING3 levels were low, but under stressed conditions, p53 was
released and ING3 occupied the TSS more avidly (Figure 7K).
Together, these results suggest that p53 and ING3 do not occupy
chromatin regions at the same time in agreement with the
observation that the two factors do not seem to interact.
Although ING3 associates with TIP60 (Doyon et al, 2006) and
AR (Nabbi et al, 2017), this interaction occurs in the cytoplasm
and regulates acetylation-dependent AR shuttling (Nabbi et al,
2017). Moreover, although AR was present at the ARE of KLK2
and KLK3 (PSA), ChIP experiments did not detect enrichment of
ING3 at these sites (Supplementary Figure S5), suggesting that
ING3 is not recruited via AR. Indeed, ING3 associates with the TSS
(H3K4me3 marked region) of genes while AR binds the ARE
regions, thus suggesting that ING3 can also regulate AR-responsive
transcription independently of AR. Indeed, our silencing experi-
ments (Figures 4D–G and Supplementary Figure S3) clearly show
that ING3 is required for the proliferation of both ARþ (e.g.,
LNCaP) and AR (e.g., PC3) cells, demonstrating that ING3,
although able to regulate some AR-responsive genes, regulates cell
proliferation through AR-independent pathways. Indeed, ING3
regulates the expression of p53-responsive genes (Figures 5D–F) as
well as several cell cycle genes (Figure 4A).
Although the ING3 siRNAs had consistent effects on most AR-
responsive genes (e.g., KIF20A, PSA, TMPRSS2), they had different
effects on KLK2. Interestingly, KLK2 and KLK3 (PSA) are located
B12 kb apart on chromosome 19. However, the chromatin
landscape seems highly divergent. Specifically, a clear TSS
(H3K4me3 double peak) is found at KLK2, whereas no such
regulatory element is found in the ENCODE project data at KLK3
and very few transcription factors bind the KLK3 locus compared
with KLK2. We hypothesise that the difference in KLK2 and KLK3
response to ING3 siRNAs may be a reflection of different
mechanisms regulating these genes.
In agreement with ING4 and ING5 being required for normal
cell cycle progression (Doyon et al, 2006), we observed that ING3
is also required for cellular proliferation of cancer cells.
Importantly, our ING3-dependent proliferation results are in line
with a recent publication showing that ING3 protein levels
correlate with the proliferation status of cells (Nabbi et al, 2015).
Our data from cell line models showing the requirement of ING3
for the proliferation of cancer cells are also in agreement with the
elevated levels of ING3 in a subset of tumours in cancer patients.
The requirement of ING3 for the proliferation of breast cancer,
ovarian cancer, and PC cells and its elevated levels in prostate
tumours, which also correlate with poor survival, define ING3 as a
novel marker of poor prognosis and a potential therapeutic target.
Overexpression-based studies and sequence similarities to the
tumour-suppressor ING1 led to the hypothesis that ING3 may be a
tumour suppressor. However, our investigations using a more
physiologically relevant ex vivo explant model define ING3 as an
oncoprotein, which is supported by transformation and prolifera-
tion assays.
Although mutations of ING proteins are rarely reported
(Cerami et al, 2012; Gao et al, 2013), there are many cases of
either amplification or deletion (Supplementary Figure S8). In
agreement with our observations that ING3 levels are elevated in
PC compared with BPH patient samples, most PC databases report
ING3 amplification (Supplementary Figure S8). Interestingly, one
case of mutation could be found in a PC patient, a nonsense
mutation at E125, which likely results in a truncated form lacking
the PHD and 70% of the protein.
Together, our data demonstrate that ING3 is required for
proliferation of cancer cells via an intricate transcriptional network
involving cell cycle regulators, androgen, and p53 signalling
pathways. Importantly, elevated ING3 expression in cancer
patients and correlation with poor survival support ING3 as a
biomarker and potentially a therapeutic target in both early and
advanced treatment-resistant cancer patients. Our results redefine
ING3 as an INducer of Growth (ING) and an oncoprotein.
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